FDAorphan designation65% confidence
Medical Products for Rare Diseases and Conditions
Source: FDA
Why This Matters
Why this matters: provides agency context on orphan designation that may shape timing or evidence expectations for Boehringer Ingelheim.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · COVID-19
- Sub-indication
- General
Related signal: Boehringer Ingelheim's BI 764198 Trial Examines Formulation Impact on Bioavailability